
Newsmakers
Hoth Therapeutics (NASDAQ: HOTH) to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities
Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK, June 5, 2025 — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough […]